CALCIUM CHLORIDE- calcium chloride injection 
Amneal-Agila, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Calcium Chloride Intravenous Infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER

Calcium Chloride Intravenous Infusion 10% w/v

Calcium chloride

Read all of this leaflet carefully before you are given this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions please ask your doctor or pharmacist.
  • If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1.      What Calcium Chloride Intravenous Infusion 10% w/v is and what it is used for

2.      Before Calcium Chloride Intravenous Infusion 10% w/v is given

3.      How Calcium Chloride Intravenous Infusion 10% w/v is given

4.      Possible side effects

5.      How to store Calcium Chloride Intravenous Infusion 10% w/v

6.      Further information

1.      What Calcium Chloride Intravenous Infusion is and what it is used for

Calcium Chloride is a mineral salt, which is administered to increase the blood levels of Calcium in the body and to get the heart working where potassium levels are too high.

Calcium Chloride is used:

2. Before Calcium Chloride Intravenous Infusion is given

 DO NOT use Calcium Chloride Intravenous Infusion if:

Take special care with Calcium Chloride Intravenous Infusion if:

If any of the above applies to you or your child, please consult your doctor.

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Medicines that may interact with Calcium Chloride Intravenous Infusion include:

Pregnancy and breast-feeding

If you are pregnant, likely to become pregnant or breast-feeding you must tell your doctor before taking this medicine.

Driving and using machines

There is no known effect of Calcium Chloride Intravenous Infusion on driving or using machines.

3.      How Calcium Chloride Intravenous Infusion is given

Your doctor or nurse will administer the injection slowly through a vein (intravenous).

Adults (including the elderly)

Children

If you are given more Calcium Chloride Intravenous Infusion than you should be

As this medicine will be given to you whilst you are in hospital, it is unlikely that you will be given too little or too much, however, tell your doctor or pharmacist if you have any concerns.

4. Possible side effects

Like all medicines, Calcium Chloride Intravenous Infusion can cause side effects, although not everybody gets them.

Possible side effects include:

If any of these side effects get serious, or if you notice any side effects not listed in this leaflet please tell your doctor as soon as possible as this may be a sign of overly calcium blood levels (hypercalcemia).

5.      How to store Calcium Chloride Intravenous Infusion

Keep out of the reach and sight of children.

Store below 25°C.

Do not use after expiry date has passed. The doctor or nurse will check that the expiry date on the label has not passed before you are given Calcium Chloride Intravenous Infusion. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicine no longer required. These measures will help protect the environment.

6.      Further information

What Calcium Chloride Intravenous Infusion contains

The active ingredient is Calcium Chloride Ph.Eur. (1g)

The other ingredient is Water for injection BP (10 mL).

What Calcium Chloride Intravenous Infusion looks like and the contents of the pack.

The medication is supplied as a single 10 mL prefilled syringe in a plastic box.

(NDC 53150-697-01)

Manufactured by:
Agila Specialties Private Limited,
Bangalore - INDIA.

Distributed by:
Amneal-Agila, LLC
Glasgow, KY 42141

Revision: 03-2013

Healthcare Professional Letter

IMPORTANT DRUG INFORMATION

May XX, 2013

Re:   URGENT – 10% Calcium Chloride Injection, USP 10 mL

Unit of Use Syringe Shortage Update

Dear Healthcare Professional,

Due to the current critical shortage of 10% Calcium Chloride Injection, USP 10 mL Unit of Use Syringe in the United States (US) market, Agila Specialties Private Limited (Agila) is coordinating with the Food and Drug Administration (FDA) to increase the availability of 10% Calcium Chloride Injection, USP 10 mL Unit of Use Syringe. In cooperation with the FDA, on behalf of Agila, Amneal-Agila, LLC (Amneal Agila) has initiated temporary importation of a non-FDA approved Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe from Agila’s FDA inspected facility in Bangalore, India to the US market.

Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe contains the same active ingredient, Calcium Chloride, in the same strength and concentration as Hospira, Inc.’s FDA approved 10% Calcium Chloride Injection, USP 10 mL Unit of Use Syringe. Each ml of Agila’s product contains 100 mg (1.4 mEq/mL) of Calcium Chloride dihydrate (1.4mEq each of Calcium Ca++ and Cl-) in water for injection.

At this time, no other entity except Amneal-Agila is authorized by the FDA to import or distribute a non-FDA approved Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe. Any sales of this product from any other entity other than Amneal-Agila or a distributor or re-seller authorized by Amneal-Agila will be considered in violation of the Federal Food, Drug and Cosmetic Act and may be subject to enforcement by the FDA.

Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe is approved in the United Kingdom and is dispensed with a Medication Guide. The information on the medication guide differs from the full prescribing information for Hospira Inc.’s FDA approved product. For full prescribing information, please refer to the FDA approved package insert for the full prescribing information for Hospira Inc.’s product at:

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4c65e48-85f8-4dcf-6281-06e40959cc79

It is important to note the following Contraindications, Warnings and Precautions in the US FDA

approved package insert for Hospira Inc.’s product:

CONTRAINDICATIONS

Calcium chloride is contraindicated for cardiac resuscitation in the presence of ventricular fibrillation or in patients with the risk of existing digitalis toxicity. Calcium chloride is not recommended in the treatment of asystole and electromechanical dissociation.

WARNINGS

10% Calcium Chloride Injection, USP is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.

Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

Do not administer unless solution is clear and seal is intact. Discard unused portion.

Because of its additive effect, calcium should be administered very cautiously to a patient who is digitalized or who is taking effective doses of digitalis or digitalis-like preparations. Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope.

The attached chart highlights the differences in the prescribing information between the FDA-approved Calcium Chloride and Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe.

Please note that the barcode used for Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe may not be appropriately recognized by scanning systems used in the United States. Institutions should confirm that barcode systems do not provide incorrect information when the product is scanned. Alternative procedures should be followed to assure that the correct drug product is being used and administered to individual patients.

To order Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe, please contact Customer Service at 1-866-525-7270 or order through the below wholesalers:

AmeriSource Bergen – Order number –

Cardinal Health – Order number –

McKesson Wholesale – Order number –

To report adverse events or medication errors for patients who have used Amneal-Agila’s Calcium Chloride Intravenous Infusion 10% w/w 10 mL Unit of Use Syringe, please contact Drug Safety by telephone at 1-877-835-5472 (Press Option 1) or online @ drugsafety@amneal.com. Adverse reactions may also be reported to the FDA’s MedWatch Adverse Reporting Program either online, by regular mail or fax:

Sincerely,

Amneal-Agila Pharmaceuticals

PRINCIPAL DISPLAY PANEL

 syringe label

PRINCIPAL DISPLAY PANEL

container label 

PRINCIPAL DISPLAY PANEL

crash box 

CALCIUM CHLORIDE 
calcium chloride injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:53150-697
Route of AdministrationINTRAVENOUSDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CALCIUM CHLORIDE (CALCIUM CATION) CALCIUM CHLORIDE100 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
WATER 
CALCIUM HYDROXIDE 
HYDROCHLORIC ACID 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:53150-697-011 in 1 CARTON
110 mL in 1 SYRINGE, GLASS
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE05/31/2013
Labeler - Amneal-Agila, LLC (078578876)

Revised: 6/2013
Document Id: d94a88ed-96a4-41ee-84fb-9514c0987b85
Set id: e42aec6b-5419-4c70-8c2a-d5c87c0a0374
Version: 6
Effective Time: 20130618
 
Amneal-Agila, LLC